LAG525 + carboplatin + spartalizumab

LAG525 + carboplatin + spartalizumab is an investigational combination therapy for advanced solid tumors, particularly triple-negative breast cancer (TNBC). The regimen combines three agents with distinct mechanisms:\n\n- **LAG525 (ieramilimab)** is a humanized IgG4 monoclonal antibody targeting lymphocyte activation gene 3 (LAG-3), an inhibitory immune checkpoint receptor on T cells. By blocking LAG-3, it enhances T-cell activation and anti-tumor immunity.\n \n- **Spartalizumab (PDR001)** is a humanized IgG4 monoclonal antibody that targets programmed cell death protein 1 (PD-1) on immune cells, preventing its interaction with PD-L1/PD-L2 and thereby promoting immune-mediated tumor cell killing.\n\n- **Carboplatin** is a platinum-based chemotherapy agent that induces DNA crosslinking and apoptosis in rapidly dividing tumor cells.\n\nThe rationale for this combination stems from the potential synergistic effect of dual checkpoint inhibition (LAG3 and PD1 blockade) alongside chemotherapy-induced immunogenic modulation of the tumor microenvironment. This approach aims to enhance anti-tumor responses in patients who may not respond to single-agent immunotherapy or chemotherapy alone. Clinical trials have evaluated this combination primarily in advanced/metastatic TNBC as first or second-line therapy[3][8][9].

Brand names

spartalizumab

Other names

ieramilimab + carboplatin + spartalizumab